{"entity":{"id":"lb4330","kind":"drug","name":"LB4330","aka":[],"tldr":"LB4330 is an experimental fusion protein from L & L Bio, Ningbo, China in phase 2 trials, aimed at Claudin 18.2.","summary":"LB4330 is a fusion protein developed by L & L Bio, Ningbo, China. Its target is Claudin 18.2 (the sponsor names Claudin18.2 x IL-10). The sponsor states: Anti-Claudin18.2/IL-10 fusion protein combining tumour-antigen targeting with an immunomodulatory cytokine, given in combination with LB1410. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06468358, plans to enrol 194 participants with primary completion expected 2026-12-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of LB4330","url":"https://clinicaltrials.gov/search?intr=LB4330"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["cldn18-2"],"drugs":[],"companies":["hutchmed"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06468358"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"fusion protein","mechanism":"Anti-Claudin18.2/IL-10 fusion protein combining tumour-antigen targeting with an immunomodulatory cytokine, given in combination with LB1410.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/lb4330/","neighbours":{"target":[{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/"},{"id":"il10","kind":"target","name":"Interleukin-10 (IL10)","route":"/targets/il10/"}],"company":[{"id":"hutchmed","kind":"company","name":"Hutchmed","route":"/companies/hutchmed/"}],"trial":[{"id":"nct06468358","kind":"trial","name":"A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors","route":"/trials/nct06468358/"}]}}